INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA

Core Viewpoint - STAAR Surgical Company is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q4 and full year 2024 [1][2]. Financial Performance - For Q4 2024, STAAR reported GAAP earnings per share of -$0.69, missing consensus estimates by $0.55 [2]. - The company's revenue for the quarter was $48.95 million, which fell short of consensus estimates by $28.52 million [2]. - The company attributed its poor performance to "fluctuating demand in China" [2]. Market Reaction - Following the announcement of the financial results, STAAR's stock price dropped by $5.40 per share, or 24.68%, closing at $16.48 per share on February 12, 2025 [3].